03/08/2026
A milestone worth celebrating for the brain tumour community. ๐
For the first time in more than 20 years, eligible patients diagnosed with IDH-mutant astrocytoma or oligodendroglioma, a rare and incurable brain cancer, will have access to a new targeted treatment through the Pharmaceutical Benefits Scheme (PBS).
Voranigo (vorasidenib) โ which can help slow tumour growth โ will now be subsidised for eligible patients, significantly reducing the cost of this treatment and improving access for those who may benefit from it.
The NeuroSurgical Research Foundation and Brain Tumour Research SA were proud to stand alongside our colleagues in the Australian Brain Tumour Collaborative for this important announcement. This achievement was many years in the making and we are grateful to Servier for their ongoing support and advocacy to make this possible.
A special thank you to Leah for sharing her story โ a powerful reminder of why continued research and collaboration are so vital, and the many patients and families who generously shared their time and lived experience to support this process. This win belongs to our brain cancer community - your voice truly makes a difference.
Watch the 9 News coverage here: https://youtu.be/QdVsK1w8ww4?si=1s0lHCy1-YSBesBg
If you think you may meet the criteria for Voranigoยฎ, please speak with your treating clinician.
A drug that can help hundreds of Australians living with a rare for...